Pembrolizumab + Enfortumab vedotin (EV) + Gemcitabine + Cisplatin
Phase 3Completed 0 views this week 0 watching⚡ Active
Interest: 40/100
40
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Bladder Cancer
Conditions
Bladder Cancer
Trial Timeline
Apr 21, 2021 → Oct 27, 2025
NCT ID
NCT04700124About Pembrolizumab + Enfortumab vedotin (EV) + Gemcitabine + Cisplatin
Pembrolizumab + Enfortumab vedotin (EV) + Gemcitabine + Cisplatin is a phase 3 stage product being developed by Astellas Pharma for Bladder Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT04700124. Target conditions include Bladder Cancer.
What happened to similar drugs?
20 of 20 similar drugs in Bladder Cancer were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
17
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04700124 | Phase 3 | Completed |
Competing Products
20 competing products in Bladder Cancer